Drug startups coalesce around condensates
Elie Dolgin • February 9, 2021
Once a neglected biological phenomenon, condensates are attracting interest from small companies and large pharmas.
Three startups debuted in late 2020, all aiming to treat disease by manipulating the physiochemical and regulatory processes in cells that drive membrane-less hubs associated with disease pathogenesis. The field’s frontrunner, Dewpoint Therapeutics, also signed a major research pact last month with Pfizer — Dewpoint’s third such deal with a large pharma partner since the company’s inception two years ago.
Continue reading at Nature Biotechnology.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.